Risks of muscle toxicity among specific statin therapies
| Generic statin name | Number of cases with events* | Person-years | Incidence † |
|---|---|---|---|
| All statins | 43 | 42193 | 1.02 (0.76 to 1.37) |
| Atorvastatin | 17 | 15776 | 1.08 (0.67 to 1.73) |
| Rosuvastatin | 15 | 8655 | 1.73 (1.04 to 2.87) |
| Pravastatin | 5 | 11121 | 0.45 (0.19 to 1.08) |
| Pitavastatin | 3 | 2883 | 1.04 (0.34 to 3.23) |
| Simvastatin | 2 | 2123 | 0.94 (0.24 to 3.77) |
| Fluvastatin | 1 | 1635 | 0.61 (0.09 to 4.34) |
*Cases were defined by either criteria A (diagnosis of ‘myositis’ or ‘rhabdomyolysis’) or B (creatine kinase concentration >10× the upper limit of the normal range).
†Data shown as per 1000 person-years with 95% CI.